SCHEMBL3593677

SCHEMBL3593677

Cc1c(C(=O)N(C)Cc2ccc3ncccc3c2)[nH]c(C(N)=O)c1S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 6/20 0.38
SPR P35270 1/20 0.38
BRAF P15056 1/20 0.37
PDK1 Q15118 2/20 0.37
MAPK1 P28482 2/20 0.37
ALDH1A1 P00352 1/20 0.37
RAB9A P51151 1/20 0.37
TACR1 P25103 3/20 0.37
USP30 Q70CQ3 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TYMS P04818 1/20 0.35
HDAC3 O15379 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
HDAC4 P56524 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583754 0.86 SPR (0.41) NAMPTSPRPDK1MAPK1ALDH1A1
SCHEMBL3590929 0.85 SPR (0.40) NAMPTSPRPDK1MAPK1ALDH1A1
SCHEMBL3585551 0.85 KDM4E (0.43) PDK1ALDH1A1TACR1HDAC3HDAC4
SCHEMBL3584400 0.83 SPR (0.38) NAMPTSPRPDK1MAPK1ALDH1A1
SCHEMBL3574643 0.80 SPR (0.38) NAMPTSPRPDK1MAPK1ALDH1A1
SCHEMBL3579566 0.80 PDK1 (0.43) NAMPTSPRPDK1MAPK1ALDH1A1
SCHEMBL3587158 0.79 PDK1 (0.42) NAMPTSPRPDK1MAPK1ALDH1A1
SCHEMBL3586733 0.79 SPR (0.37) SPRPDK1MAPK1ALDH1A1RAB9A
SCHEMBL3581443 0.79 PDK1 (0.41) NAMPTSPRPDK1MAPK1ALDH1A1
SCHEMBL3586109 0.78 PDK1 (0.42) NAMPTSPRPDK1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP claimed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E NAMPT 76/4885SPR 217/4885BRAF 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.